Scripps Research announced a new clinical trial Thursday that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID, the debilitating chronic condition diagnosed in an estimated 20 million Americans and about 400 million people worldwide.

Developed to help people with type 2 diabetes control their blood sugar levels, these GLP-1 medications have generated billions of dollars in revenue for their ability to slow the pace of digestion and reduce appetite, helping millions worldwide lose weight.

But, as always happens with big pharma blockbusters, the research community is busy exploring other possible applications for this class of compounds, with clinical trials underway or forming in cardiovascular disease, chronic kidney d

See Full Page